Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction
Wen Tang(Cleveland Clinic), Samuel L. Murphy(Integrated BioTherapeutics (United States)), Justin L. Grodin(The University of Texas Southwestern Medical Center), Aferdita Spahillari(Massachusetts General Hospital), Matthew T. Wheeler(Stanford University), Shalabh Singhal(Integrated BioTherapeutics (United States)), Neal Solomon(Integrated BioTherapeutics (United States)), Nancy K. Sweitzer(National Heart Lung and Blood Institute), J. T. Steiner(Oregon Health & Science University), Amanda McEwen, Mahwash Kassi(Methodist Hospital)
Cited by 4
Related Papers
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association
|Circulation|2017|1.8k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k